|Bid||115.1800 x 300|
|Ask||115.2000 x 400|
|Day's Range||113.6300 - 116.6900|
|52 Week Range||94.4200 - 127.6400|
|PE Ratio (TTM)||43.41|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study, bringing the U.S. biotech a step closer to launching a potential blockbuster. The drug, ozanimod, reduced annualized relapse rate in patients with relapsing multiple sclerosis, compared to Biogen Inc's Avonex, the company said on Monday. Celgene's shares were marginally down in premarket trading.
The trial enrolled 1,313 RMS patients in 21 countries for two years of study.
Celgene Corp. shares rose about 1% premarket before surrendering their gains, after the company reported positive results from a late-stage trial of a treatment for multiple sclerosis. Celgene said the ...